Kyun-Seop Bae

Prof. Dr. Kyun-Seop Bae

Clinical Pharmacology and Therapeutics, University of Ulsan, Ulsan, Republic of Korea
orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2009 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
HLHyeong-Seok Lim
Hyeong-Seok Lim
JIJeong-Soo Im
Jeong-Soo Im
Joo-Youn ChoJoo-Youn Cho
Joo-Youn Cho
KBKyun-Seop Bae
Kyun-Seop Bae
TKTerry A. Klein
Terry A. Klein
JPJae-Won Park
Jae-Won Park
Hydroxychloroquine (HCQ) is an antimalarial drug used as chemoprophylaxis against malaria caused byPlasmodium vivaxin the Republic of Korea Army (ROKA). In this study, we evaluated the pharmacokinetics (PK) of HCQ and its metabolites and the relationship between the PK of HCQ and the effect of treatment of HCQ on vivax malaria in South Koreans. Three PK studies of HCQ were conducted with 91 healthy subjects and patients with vivax malaria. Plasma concentrations were analyzed by noncompartmental and mixed-effect modeling approaches. A two-compartment model with first-order absorption best described the data. The clearance and the central and peripheral volumes of distribution were 15.5 liters/h, 733 liters, and 1,630 liters, respectively. We measured the plasma concentrations of HCQ in patients with prophylactic failure of HCQ and compared them with the prediction intervals of the simulated concentrations for HCQ from the final PK model built in this study. In 71% of the patients with prophylactic failure, the plasma concentrations of HCQ were below the lower bounds of the 95% prediction interval, while only 8% of them showed higher levels than the upper bounds of the 95% prediction interval. We report that a significant cause of prophylactic failure among the individuals in ROKA was ascribed to plasma concentrations of HCQ lower than those predicted by the PK model. However, prophylactic failure despite sufficient plasma concentrations of HCQ was confirmed in several individuals, warranting continued surveillance to monitor changes in the HCQ susceptibility ofPlasmodium vivaxin the Republic of Korea.

22 August 2019 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
SHSungpil Han
Sungpil Han
HCHee Youn Choi
Hee Youn Choi
YKYo Han Kim
Yo Han Kim
JNJi Yeon Nam
Ji Yeon Nam
BKBongtae Kim
Bongtae Kim
KBKyun-Seop Bae
Kyun-Seop Bae
Summary: Background: Tegoprazan (CJ‐12420) is a potassium‐competitive acid blocker (P‐CAB) with therapeutic potential for gastro‐oesophageal reflux disease (GERD) by reversibly suppressing gastric H+/K+‐ATPase.Aims: To investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of tegoprazanMethods: A phase I, randomised, double‐blind and placebo‐controlled clinical trial was conducted in 56 healthy male subjects without Helicobacter pylori infection. In the single ascending dose study, 50, 100, 200 and 400 mg tegoprazan were administered to 32 subjects. In the multiple ascending dose study, 100 and 200 mg tegoprazan were administered every 24 hours to each of the eight subjects for 7 days. In the comparative pharmacodynamics study, 40 mg esomeprazole was administered to eight subjects every 24 hours for 7 days. The assessment included safety, tolerability, pharmacodynamics through monitoring of 24‐hour gastric pH and pharmacokinetics of tegoprazan in plasma and urine.Results: Tegoprazan was generally well tolerated. Most adverse events reported in the study were mild in intensity and resolved without any sequelae. Exposure to tegoprazan increased in a dose‐proportional manner. Multiple dosing with tegoprazan showed no accumulation in plasma on day 7. The pharmacodynamic analysis revealed that tegoprazan showed rapid, dose‐dependent gastric acid suppression.Conclusions: Tegoprazan was well tolerated and showed rapid and potent gastric acid suppression. This supports the further development of tegoprazan as a treatment for acid‐related disorders.

6 October 2006 in Journal of Neuroimaging
Verified
Journal Article
Closed access
PDF file
JKJee‐Hyun Kwon
Jee‐Hyun Kwon
JKJong S. Kim
Jong S. Kim
DKDong‐Wha Kang
Dong‐Wha Kang
KBKyun-Seop Bae
Kyun-Seop Bae
SKSun U. Kwon
Sun U. Kwon

1 April 2001 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
KYKyung‐Sang Yu
Kyung‐Sang Yu
DYDong-Seok Yim
Dong-Seok Yim
Joo-Youn ChoJoo-Youn Cho
Joo-Youn Cho
SPSoon Seong Park
Soon Seong Park
JPJi Young Park
Ji Young Park
SSSang‐Goo Shin
Sang‐Goo Shin
Background Moclobemide, an antidepressant with selective monoamine oxidase‐A inhibitory action, is known to be metabolized by CYP2C19 and is also reported to be an inhibitor of CYP2C19, CYP2D6, and CYP1A2. To confirm the involvement of CYP2C19, we performed a pharmacokinetic interaction study. Methods The effect of omeprazole on the pharmacokinetics of moclobemide was studied in 16 healthy volunteers. The volunteer group comprised 8 extensive metabolizers and 8 poor metabolizers of CYP2C19, which was confirmed by genotyping. Subjects were randomly allocated into two sequence groups, and a single‐blind, placebo‐controlled, two‐period crossover study was performed. In study I, a placebo was orally administered for 7 days. On the eighth morning, 300 mg of moclobemide and 40 mg of placebo were coadministered with 200 mL of water, and a pharmacokinetic study was performed. During study II, 40 mg of omeprazole was given each morning instead of placebo, and pharmacokinetic studies were performed on the first and eighth day with 300 mg of moclobemide coadministration. Results The inhibition of moclobemide metabolism was significant in extensive metabolizers even after a single dose of omeprazole. After daily administration of omeprazole for 1 week, the pharmacokinetic parameters of moclobemide and its metabolites in extensive metabolizers changed to values similar to those in poor metabolizers. In poor metabolizers, no remarkable changes in the pharmacokinetic parameters were observed. Conclusion Our results show that CYP2C19 is an important enzyme in the elimination of moclobemide and that it is extensively inhibited by omeprazole in extensive metabolizers, but not in poor metabolizers. Clinical Pharmacology & Therapeutics (2001) 69, 266–273; doi: 10.1067/mcp.2001.114231

1 January 2004 in The Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
KYKyung‐Sang Yu
Kyung‐Sang Yu
KBKyun-Seop Bae
Kyun-Seop Bae
JSJi‐Hong Shon
Ji‐Hong Shon
Joo-Youn ChoJoo-Youn Cho
Joo-Youn Cho
SYSo‐Young Yi
So‐Young Yi
BMByoung‐Seok Moon
Byoung‐Seok Moon

1 June 2010 in Clinical Therapeutics
Verified
Journal Article
Closed access
JJJinah Jung
Jinah Jung
SCSangmin Choi
Sangmin Choi
SCSang Heon Cho
Sang Heon Cho
JGJong-Lyul Ghim
Jong-Lyul Ghim
AHAekyung Hwang
Aekyung Hwang
HLHyeong-Seok Lim
Hyeong-Seok Lim